Market Overview - US stock indices experienced a rise, with the Dow Jones up 0.94%, Nasdaq up 0.97%, and S&P 500 up 0.8% [1] - The VIX index decreased by 1.01% to 16.59, indicating reduced market volatility [1] - The US dollar index fell by 0.41% to 97.3, while the yield on the 10-year Treasury bond dropped by 1.142% to 4.243% [1] - Spot gold decreased by 0.13% to $3327.6 per ounce, and Brent crude oil rose by 0.42% to $66.68 [1] Industry & Stocks - Most major sectors in the S&P 500 saw gains, with energy up 1.43%, communications up 1.16%, and technology up 0.78% [1] - Chinese concept stocks showed mixed results, with TSMC up 0.57% and Pinduoduo down 1.3% [1] Technology Sector - Major tech stocks mostly rose, with Nvidia up 0.46%, Microsoft up 1.05%, and Amazon up 2.42% [2] - Coinbase (COIN) surged by 5.54%, while Robinhood (HOOD) increased by 2.14% [2] Company News - Nike's Q4 revenue reached $11.1 billion, exceeding analyst expectations of $10.72 billion, leading to a post-market surge of over 10% [5] - AeroVironment reported a 40% year-over-year revenue increase to $27.51 million, surpassing market expectations, and is expected to benefit from NATO's increased defense spending [6] - Core Scientific is in talks for acquisition by CoreWeave, with CoreWeave's stock rising by 33.01% [3] Regulatory Developments - The FHFA announced plans to allow cryptocurrencies as collateral for mortgage applications, marking a significant shift in asset evaluation standards [4]

Core Viewpoint - Novo Nordisk has ended its distribution partnership with Hims & Hers Health over the latter's sale of compounded drugs, specifically the weight loss therapy Wegovy (semaglutide), which led to a significant drop in Hims & Hers' stock price [1][2] Group 1: Company Actions and Reactions - Novo Nordisk accused Hims & Hers of not adhering to legal standards and allegedly selling compounded drugs under the guise of "personalization" [1] - Hims & Hers CEO Andrew Dudum stated that the company will continue to offer affordable compounded Wegovy despite the termination of the partnership, emphasizing the company's commitment to customer interests [1][2] - Dudum highlighted that Novo Nordisk pressured Hims & Hers to direct patients towards the branded Wegovy, regardless of clinical appropriateness for patients [2] Group 2: Regulatory Context - Novo Nordisk's executive, Ludovic Helfgott, mentioned that there was an agreement to stop the large-scale production of compounded drugs, which was not honored by Hims & Hers [2] - According to U.S. regulations, pharmaceutical companies are allowed to produce compounded drugs in large quantities if there is a drug shortage, which was the case for Wegovy until it was removed from the shortage list by the FDA in April [2]